TrickeyA, SabinCA, BurkholderG, et al.Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies. Lancet HIV, 2023; 10(5):e295–e307.
3.
SzalavitzM. It’s cruel to take away people’s H.I.V. medication. New York Times; 2026.
4.
LaurenceJ. Ending AIDS: HIV, ART, and PrEP in the context of new global realities. AIDS Patient Care STDS, 2025; 39(6):213–214.
5.
AfolabiJM, KiraboA. HIV and cardiovascular disease. Circ Res, 2024; 134(11):1512–1514.
6.
DurstenfeldMS, ThakkarA, JeonD, et al.HIV-associated heart failure: Phenotypes and clinical outcomes in a safety-net setting. J Am Heart Assoc, 2024; 13:e036467.
7.
GrinspoonSK, FitchKV, ZanniMV, et al.; REPRIEVE Investigators. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med, 2023; 389(8):687–699.
8.
BeaversC, PauAK, GliddenD, et al.Statin therapy as primary prevention for person with HIV: A synopsis of recommendations from the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel. Ann Intern Med, 2025; 178(6):847–857.
9.
WalpertAR, GuptaM, DunderdaleCN, et al.Exploring the PREVENT HF score and myocardial function among persons with HIV. AIDS, 2025; 39(11):1592–1597.
10.
SubramaniK, BabiiD, ColeB, et al.Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling. JCI Insight, 2026; 5:e198647.
11.
TalathiR, AnekweCV, ToribioM. Epidemiology of obesity among people with HIV. Curr Opin HIV AIDS, 2024; 19(1):1–5.
12.
LaurenceJ, SubramaniK, BabiiD, et al.SGLT2 inhibitor dapagliflozin attenuates HIV-linked cardiac fibrosis, steatosis and diastolic dysfunction in a mouse model via inhibition of TGFβ signaling. AIDS, 2026 in press.
13.
SviridovD, BukrinskyM. Neuro-HIV—new insights into pathogenesis and emerging therapeutic insights. Faseb J, 2023; 37:e23301.
14.
ShorerEF, DastgheybRM, RubinLH, et al.Parkinsonism in people with virally suppressed HIV. Lancet HIV, 2026; 13(3):e194–e206.
15.
MustafaM, MusselmanD, JayaweeraD, et al.HIV-associated neurocognitive disorder (HAND) and Alzheimer’s disease pathogenesis: Future directions for diagnosis and treatment. IJMS, 2024; 25(20):11170.
16.
LamJO, FanD, PothamsettyN, et al.Dementia incidence and prevalence in older ults with HIV: A 23-year retrospective cohort study. AIDS, 2026; 40(4):486–495.
17.
NguyenHD, KimW-K. New genetic insights into HIV-associated neurocognitive disorder and Alzheimer’s disease. Genes Dis, 2025; 12(5):101576.
18.
ObareLM, TemuT, MallalSA, et al.Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circ Res, 2024; 134(11):1515–1545.
19.
LaurenceJ, ElhadadS, AhamedJ. HIV-associated cardiovascular disease: Importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies. Open Heart, 2018; 5(2):e000823.
20.
LuMT, RibaudoH, FoldynaB, et al.; REPRIEVE Trial Writing Group. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: Mechanistic substudy of the REPRIEVE randomized clinical trial. JAMA Cardiol, 2024; 9(4):323–334.
21.
CummingsJL, AtriA, ZetterbergH, et al.Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): Two phase 3, randomized, placebo-controlled trials. Lancet, 2026:S0140; doi: oreg/10.1016/S0140-6736(26)00459-9
22.
Editorial. Neurodegenerative disease need more mechanism-informed trials. Nat Med, 2026; 32:381.
23.
FischerL, ParkerD, MaboudianS, et al.Longitudinal biomarker studies in human neuroimaging: Capturing biological change of Alzheimer’s pathology. Alzheimer’s Res Ther, 2026; 18:13.
24.
ChemparthyDT, KannanM, GordonL, et al.Alzheimer’s-like pathology at the crossroads of HIV-associated neurological disorders. Vaccines (Basel), 2021; 9(8):e30.
25.
HiransuthikulA, ThanapornsangsuthP, LuechaipanitW, et al.; HIV‐NAT 006 and 207 study team. Blood-based Alzheimer’s disease biomarkers and cognitive trajectories in older people with HIV with undetectable viral loads. Alzheimers Dement, 2026; 22(1):e71101.
26.
NaghaviMH. “APP”reciating the complexity of HIV-induced neurodegenerative diseases. PLoS Pathog, 2018; 14(10):e1007309.
27.
TejedaM, FarrellJ, ZhuC, et al.DNA from multiple viral species is associated with Alzheimer’s disease risk. Alzheimers Dement, 2024; 20(1):253–265.
28.
OnisiforouA, ZanosP. From viral infections to Alzheimer’s disease: Unveiling the mechanistic links through systems bioinformatics. J Infect Dius, 2024; 230(Supplement_2):S128–S140.
29.
GannonPJ, Akay-EspinozaC, YeeAC, et al.HIV protease inhibitors alter amyloid precursor protein processing via β-site amyloid precursor protein cleaving enzyme-1 translational up-regulation. Am J Pathol, 2017; 187(1):91–109.
30.
LakeJE, CurrierJS. Metabolic disease in HIV infection. Lancet Infect Dis, 2013; 13(11):964–975.
31.
FrascaD, PallikkuthS. Metabolic deficits and immune dysfunction in aging people living with HIV. Immunometabolism, 2025; 7(4):e00071.
32.
MarquineMJ, KamalyanL, ZlatarZZ, et al.Disparities in metabolic syndrome and neurocognitive function among older Hispanics/Latinos with human immunodeficiency virus. AIDS Patient Care STDS, 2024; 38(5):195–205.
33.
NightengaleS, AncesB, CinqueP, et al.Cognitive impairment in people living with HIV: Consensus recommendations for a new approach. Nat Rev Neurol, 2023; 19:424–433.
